Identification of the cognate epitopes of autoreactive T cells in Type 1 Diabetes
Identification of the cognate epitopes of autoreactive T cells in Type 1 Diabetes
批准号:
10264075
负责人:
Alok joglekar
金额:
$15.91万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-09-14 至 2022-08-31
关键词:
AffectAllelesAmericanAntigensAutoantigensAutoimmuneBindingBiological AssayCD4 AntigensCD4 Positive T LymphocytesCD8B1 geneCellsClone CellsData SetDiseaseEpitopesFOXP3 geneFoundationsFutureGene ExpressionGenesGoalsHistocompatibility Antigens Class IIHumanImmune ToleranceImmune responseImmune systemImmunotherapyIn VitroInbred NOD MiceIndividualInsulinInsulin-Dependent Diabetes MellitusIslets of LangerhansJurkat CellsKnowledgeLibrariesMajor Histocompatibility ComplexMapsMass Spectrum AnalysisMediatingMethodsMusPancreasPathogenesisPatientsPeptide/MHC ComplexPeptidesProtocols documentationPublishingRegulatory T-LymphocyteReporterResearchSamplingSignal TransductionSorting - Cell MovementSourceSpecificityT cell receptor repertoire sequencingT-Cell Antigen Receptor SpecificityT-Cell ReceptorT-LymphocyteT-Lymphocyte EpitopesT-cell receptor repertoireTechniquesTechnologyTissuesarmautoreactive T cellautoreactivitybasecell killingcentral tolerancecombatcytotoxicitydesigndiabetes pathogenesisdiabetogeniceffector T cellin vitro Assayisletmouse modelnovelnovel therapeutic interventionperipheral tolerancepreventprogramsreceptorsingle cell sequencingtargeted treatment
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
Type 1 Diabetes (T1D), affects approximately 4 million individuals worldwide, including 1.6 million Americans.
T1D is caused by progressive destruction of pancreatic cells, resulting in a significantly diminished capacity to
produce insulin. Diabetogenic CD8+ and CD4+ effector T cells that infiltrate pancreatic islets mediate cell
destruction in an antigen-specific manner by recognizing peptide epitopes presented on class I and class II MHC
molecules respectively. In contrast, regulatory T cells can suppress diabetogenic T cells, thereby preventing T1D
pathogenesis. Recognition of epitopes presented by cells is critical for the function of these autoreactive T
cells. Only a small number of self-epitopes recognized by autoreactive CD8+, CD4+ effector and regulatory T
cells in T1D have been uncovered. However, the epitopes recognized by the majority of islet-infiltrating T cells
are not known. The knowledge of these epitopes is critical for understanding disease pathogenesis and for
developing targeted therapies. Currently, widely applicable and efficient methods for T cell antigen discovery for
uncovering autoreactivity are lacking. The overarching goal of this project is to uncover the cognate epitopes of
autoreactive T cells in T1D using a novel and generalizable antigen discovery technology developed by our
group. In this proposal, we will employ T cell epitope discovery using Signaling and Antigen-presenting
Bifunctional Receptors (SABRs) to identify the epitopes recognized by effector and regulatory T cells in a mouse
model of T1D, NOD mice. We propose that constructing a library of epitopes derived from genes expressed
specifically in pancreatic cells will lead to identification of novel targets of islet-infiltrating T cells. We will
construct epitope libraries from published mass spectrometry and gene expression datasets from NOD mice.
We will obtain islet-reactive TCRs by performing single cell TCR sequencing on pancreatic islets of NOD mice.
Using cell derived SABR libraries, we will determine the cognate epitopes of islet-reactive TCRs and validate
them in vitro. The epitopes identified by these studies will lead to future studies aiming to understand the
breakage of immune tolerance by autoreactive T cells and to develop targeted immunotherapy approaches to
combat T1D. This approach will also establish the foundation for antigen discovery for T cells from T1D patient
samples in affiliation with Human Islet Research Network.
1
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Signaling via MHC: engineering immune cells with new capabilities
-
批准号:10472922
-
项目类别:
-
资助金额:$138.38万
-
财政年份:2022
-
负责人:Alok joglekar
-
依托单位:
海外基金